2026 HCP Research Report
The DTP Bridge: Integrating HCP Perspectives into Digital Access Programs
PHIL surveyed 207 U.S. healthcare providers in April 2026 to uncover what they need from pharma's digital access and direct-to-patient programs, and what the data means for brand leaders.
Download Report →HCPs Are Ready to Prescribe Through Digital Channels. Is Your Access Program Built to Earn Their Trust?
PHIL surveyed 207 U.S. healthcare providers on what drives their prescribing decisions for digital access programs. The findings highlight what moves the needle on improving patient outcomes and provider adoption.
What's Inside
Patient Affordability is the #1 Priority
1 in 2 HCPs lack confidence that patients can navigate out-of-pocket costs on their own, and top abandonment reasons include non-insurance coverage and high OOP costs. When prescribing to a digital channel, HCPs say lowest available price is the #1 most important factor they consider.
Utilization Management Support Drives Adoption
70% of HCPs cite prior authorization as the top barrier to timely, affordable access. Beyond pricing, HCPs want administrative support for utilization management tasks and dedicated patient and provider support as key program features.
“Healthcare providers are focused on delivering the best possible care for their patients. The pharma brands that win long-term are those building digital access programs that remove affordability barriers and prior authorization hurdles, while easing the operational burden on the office staff who manage these processes every day.”
Lirys CrawfordVP HCP Engagement, PHIL Inc.
See What's Possible
Ready to Build a Best-in-Class Access Program?
PHIL helps leading pharma brands launch direct-to-patient programs that exceed HCP and patient expectations and drive commercial impact at scale.
Book Demo →FAQs About the Research
How was the survey collected?
PHIL surveyed 207 U.S. healthcare providers in April 2026. An independent third-party research firm collected the sample, and responses were 100% anonymous.
What does the research cover?
The report uncovers what healthcare providers need from pharma's digital access and direct-to-patient programs, from patient affordability and out-of-pocket costs to prior authorization and utilization management support, and what the data reveals for pharma leaders.
Who is the research relevant for?
Pharmaceutical and biotechnology professionals that oversee access and commercial strategy, including leadership, patient access, commercial, brand, and innovation teams.
How do I access the research?
Access the research by filling out the form on this page.
